Home > Boards > US OTC > Miscellaneous > Rich Pharmaceuticals Inc. (RCHA)

RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Sibware Member Profile
 
Followed By 452
Posts 16,953
Boards Moderated 3
Alias Born 11/30/09
160x600 placeholder
Sibware   Wednesday, 02/04/15 08:50:05 PM
Re: stervc post# 986
Post # of 26757 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide.

Business Overview

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells (WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs, and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ).

Market Opportunities

AML

It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000. Based on this incidence, the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.


http://sec.edgar-online.com/rich-pharmaceuticals-inc/s-1-securities-registration-statement/2014/09/22/section14.aspx



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist